Site-directed mutagenesis is still a very efficient strategy to elaborate improved enzymes.
Recently, advances have been made in developing rational strategies aimed at reshaping …

Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatment,
the ability to induce immune-mediated regression of distant metastases is still poorly …

We report here the successful vectorization of a hamster monoclonal IgG (namely J43)
recognizing the murine Programmed cell death-1 (mPD-1) in Western Reserve (WR) …

It has been established that transferrin binds a variety of metals. These include toxic uranyl
ions which form rather stable uranyl-transferrin derivatives. We determined the extent to …

Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the
tumor selectivity of these oncolytic viruses must be improved. We previously constructed a …

Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been
developed to complete the cancer research arsenal and overcome the limits of current …

A34. 5, a phosphoprotein copurifying with RNA polymerase I (Pol I), lacks homology to any
component of the Pol II or Pol III transcription complexes. Cells devoid of A34. 5 hardly affect …

Abstract 53BP1 is a key transducer of the DNA damage checkpoint signal, which is required
for phosphorylation of a subset of ATM substrates and p53 accumulation. After cell …

Designing an enzyme requires, among a number of parameters, the appropriate positioning
of catalytic machinery within a substrate-binding cleft. Using the structures of cyclophilin …

About 20% of uranyl ions in serum are associated with the protein pool. A few of them such
as transferrin have been characterized, but most still have to be identified to obtain a better …